MDM2 can bind the N-terminus of p53 and promote its ubiquitination and export from the nucleus to the cytoplasm, where p53 can then be degraded by cytoplasmic proteasomes.
Introduction
The tumor suppressor protein p53 is a transcription factor and potent inhibitor of cell growth. Wild-type p53 is expressed at low levels in most cells due to a short protein half-life (1, 2) . In contrast, the p53 protein is stabilized and its levels increase in response to various stresses, including DNA damage, hypoxia, and inappropriate oncogene signaling (3) . In its active form, p53 is a tetramer that can bind DNA in a sequence-specific manner and activate gene transcription (4) . Several genes have been identified which are transcriptionally induced by p53, including p21 and bax (5, 6) . Induction of these p53-responsive genes results in either a G1 cell cycle arrest, or activation of an apoptotic cell death program, respectively (4) . p53 levels are regulated in large part by MDM2, the product of a p53-inducible gene.
MDM2 can bind the N-terminus of p53 and inhibit the activity of p53 as a transcription factor (7, 8) . Importantly, MDM2 binding also promotes the ubiquitination of p53 and its export from the nucleus to the cytoplasm, where p53 is then degraded by cytoplasmic proteasomes (9) (10) (11) .
There is some evidence that MDM2 can function as an E3 ubiquitin ligase which can transfer ubiquitin directly to p53 (12) . More recent studies have suggested a link between the ubiquitination of p53 and its export from the nucleus to the cytoplasm. In these studies, mutations that inhibited the ability of MDM2 to ubiquitinate p53 also inhibited p53 nuclear export (13, 14) . These findings led to a model in which MDM2-mediated ubiquitination activates a nuclear export signal (NES) in p53, leading to p53 nuclear export.
The stabilization of p53 that occurs in response to oncogene signaling is thought to result from increased levels of p14 ARF , a tumor suppressor protein that can form a complex with MDM2 and inhibit the ability of MDM2 to degrade p53 (15) (16) (17) . In contrast, the mechanisms by which p53 is stabilized in response to different DNA damaging agents have not been fully clarified. Certain DNA damaging agents, including UV radiation, actinomycin D, and the MDM2 can promote p53 degradation in trans 3 by guest on October 1, 2017 http://www.jbc.org/ Downloaded from alkylating agents mitomycin C (MMC) and methylmethane sulfonate (MMS) signal a decrease in MDM2 mRNA and protein levels, and a subsequent decrease in p53 ubiquitination (18, 19) .
This suggests that the stabilization of p53 in response to these agents results from a specific decrease in MDM2 gene expression. The most widely held view suggests that the DNA damage-induced stabilization of p53 results from phosphorylation of specific N-terminal sites in the p53 protein (3). For example, p53 is phosphorylated at multiple sites within or near the MDM2 binding domain in response to various DNA damaging stresses (3, 20) . Phosphorylation at serines -15 and -20 has been reported to inhibit the interaction between p53 and MDM2 (20, 21) . These results support a model in which DNA damage-induced phosphorylation at serines -15 and 20 stabilizes p53 by inhibiting p53:MDM2 binding, and thus preventing MDM2 from promoting p53 ubiquitination. The premise of this model is that modifications to p53 that inhibit its direct interaction with MDM2 will stabilize the p53 protein.
The purpose of the current study was to test the notion that direct binding between p53 and MDM2 is required for MDM2 to promote the ubiquitination, nuclear export, and degradation of p53. Towards this end, epitope-tagged p53 mutants were generated which are deficient in their ability to bind MDM2. These mutants were resistant to MDM2-mediated ubiquitination, nuclear export, and degradation when expressed with MDM2 alone. However, these same p53 mutants formed a complex with MDM2 and were efficiently ubiquitinated, exported from the nucleus, and degraded when co-expressed with MDM2 and wild-type p53. Further, this effect required MDM2 binding by the wild-type p53 protein, as well as oligomerization between wildtype p53 and the MDM2-binding deficient p53 mutants. Taken together, these results support a model whereby MDM2-binding deficient forms of p53 can bind MDM2 indirectly through oligomerization with wild-type p53, and are subsequently targeted for ubiquitination, nuclear export and degradation. These findings may have important implications regarding the DNA damage response of p53. 
Experimental Procedures
Plasmid DNAs HA-tagged wild-type p53 expression DNA was obtained from Christine Jost (Dana Farber Cancer Institute, USA). Untagged wild-type p53 and untagged p53 ∆1-42 (22) were from Peter Howley (Harvard Medical School, USA). GFP-tagged wild-type p53 has been described (14) and was obtained from Tyler Jacks (Massachusetts Institute of Technology, USA). Wild-type MDM2 DNA was obtained from Steve Grossmann (Dana Farber Cancer Institute, USA). DNA encoding myc-tagged ubiquitin (23) was obtained from Ron Kopito (Stanford University, USA). HA p53 ∆1-42 was generated by PCR using untagged p53 as a template. The 3' primer for PCR was the SP6 primer, and the 5' primer was 5'-GCGAATTCACCATGTACCCATACGATGTTCCAGATTACGCTTTGATGCTGTCCCCGG ACG-3', which encodes the HA epitope and p53 sequence initiating at amino acid 43. To construct GFP p53 ∆1-42, the GFP p53 wild-type DNA was used as a PCR template with the following primers; 5'-CCGCTGCAGACCATGTTGATGCTGTCCCCG-3' as the 5' primer, and 5'-CGGGGATCCCGGTCTGAGTCAGGCCC-3' as the 3' primer. The resulting PCR product was digested with PstI and BamHI, and cloned into the corresponding sites in the pEGFP-N1 vector (CLONTECH laboratories). The HA p53 W23S, untagged p53 ∆oligomerization domain (OD) (∆324-357), and GFP p53 ∆OD DNAs were generated using the Given that the HA p53 W23S and ∆1-42 mutants could bind MDM2 indirectly through oligomerization with wild-type p53, we next wished to determine whether these same p53 mutants could be targeted for ubiquitination when co-expressed with MDM2 and wild-type p53. Accordingly, lysates from the transfected cells were examined by immunoblot analysis with an anti-HA antibody. As shown in Fig. 3A , HA p53 W23S was not ubiquitinated when expressed with MDM2 alone in Saos-2 cells, but was efficiently ubiquitinated when expressed with both MDM2 and wild-type p53. Likewise, HA p53 ∆1-42 was not ubiquitinated when expressed with MDM2 alone (see Fig. 1B ), but was ubiquitinated when expressed with MDM2 and GFPtagged wild-type p53 (Fig. 3B) . It should be noted that only modest levels of ubiquitinated HA p53 ∆1-42 were observed in these experiments compared to the ubiquitination of HA p53 W23S. We suspect this is due to the relatively low expression level of the HA p53 ∆1-42 mutant, and to the relatively low level of MDM2 binding observed when the HA p53 ∆1-42 mutant was co-expressed with MDM2 and GFP-tagged wild-type p53 (Fig. 2B and data not shown). Nonetheless, ubiquitin conjugates of HA p53 ∆1-42 were clearly evident when this mutant was expressed with GFP-tagged wild-type p53 and MDM2. Importantly, the HA p53 W23S mutant was not ubiquitinated when expressed in Saos-2 cells with either p53 ∆1-42 or p53 ∆OD, and HA p53 ∆1-42 was not ubiquitinated when expressed in U2OS cells with either GFP p53 ∆1-42 or GFP p53 ∆OD (Figs. 3A and 3B ). Taken together, these results indicate that p53 mutants that are unable to bind MDM2 directly can be targeted for ubiquitination by MDM2 when co-expressed with both MDM2 and wild-type p53. Further, this ubiquitination requires MDM2 binding by the wild-type p53 protein, and oligomerization between wild-type p53 and the MDM2-binding deficient p53 mutants.
MDM2-mediated ubiquitination is thought to promote the export of p53 from the nucleus to the cytoplasm, where p53 can then be degraded by cytoplasmic proteasomes (13, 14) . We next wished to determine whether p53 mutants that are deficient in direct MDM2-binding could also be targeted for nuclear export when expressed with MDM2 and wild-type p53. To monitor MDM2 can promote p53 degradation in trans nuclear export, the subcellular localization of HA wild-type p53 and HA p53 ∆1-42 was determined by immunofluorescence staining when expressed alone, or when co-expressed with MDM2. As shown in Figs. 4A and 4B, both HA wild-type p53 and HA p53 ∆1-42 displayed a nuclear localization pattern when expressed alone. In contrast, HA wild-type p53 was relocalized to the cytoplasm in cells in which it was expressed with MDM2, whereas HA p53 ∆1-42 remained nuclear with MDM2 expression. Previous studies have demonstrated that the relocalization of wild-type p53 with MDM2 expression requires a nuclear export signal (NES) in p53, and can be blocked by addition of the nuclear export inhibitor leptomycin B (13, 14 and data not shown). These studies indicate that the cytoplasmic localization displayed when wildtype p53 is expressed with MDM2 results from increased p53 nuclear export. The fact that HA p53 ∆1-42 remains nuclear with MDM2 expression indicates that this mutant is resistant to nuclear export when expressed with MDM2 alone.
To test whether the MDM2 binding domain could be provided through oligomerization for p53 nuclear export, cells were transfected with DNAs encoding HA p53 ∆1-42, MDM2, and GFP-tagged p53s that were either wild-type, lacked the MDM2 binding domain (GFP p53 ∆1-42), or lacked the oligomerization domain (GFP p53 ∆OD). As shown in Figs. 5A and 5B, both HA p53 ∆1-42 and GFP wild-type p53 were nuclear when expressed alone, but were exported from the nucleus and relocalized to the cytoplasm when co-expressed with MDM2. The fact that HA p53 ∆1-42 was exported under these conditions indicates that MDM2 can promote p53 nuclear export in the absence of direct p53:MDM2 binding. In contrast, HA p53 ∆1-42 remained nuclear when expressed with MDM2 and either GFP p53 ∆1-42 or GFP p53 ∆OD, and these GFP-tagged p53 proteins also remained nuclear (Figs. 5A and 5B). These results indicate that the nuclear export of HA p53 ∆1-42 required oligomerization with wild-type p53, and MDM2 binding by the wild-type p53 protein.
Finally, we wished to determine whether a p53 mutant deficient in direct MDM2 binding could also be targeted for degradation when expressed with MDM2 and wild-type p53. To this end, HA p53 ∆1-42 was co-expressed with GFP wild-type p53, GFP p53 ∆1-42, or GFP p53 ∆OD either alone, or with MDM2. To facilitate p53 degradation, an expression DNA encoding myc-tagged ubiquitin was also included in these transfections, and the amount of MDM2 DNA transfected was in excess of the p53 DNA. As shown in Fig. 6 , steady state levels of both HA p53 ∆1-42 and GFP wild-type p53 were decreased when these two proteins were co-expressed with MDM2, indicating that MDM2 could promote the degradation of both proteins. The fact that HA p53 ∆1-42 was degraded in these experiments indicates that MDM2 can promote p53 degradation in the absence of direct p53:MDM2 binding. Importantly, HA p53 ∆1-42 was not degraded when expressed with MDM2 and either GFP p53 ∆1-42 or GFP p53 ∆OD, and these GFP-tagged p53 proteins were also not degraded. Taken together, these results support a model whereby the HA p53 ∆1-42 mutant of p53 could bind MDM2 indirectly through oligomerization with wild-type p53, and was subsequently targeted for ubiquitination ( Fig. 3) , nuclear export (Fig. 5) and degradation (Fig. 6 ).
Discussion
Wild-type p53 functions as a tumor suppressor protein by activating the transcription of genes which mediate either cell cycle arrest or apoptosis (4, 24) . Amino acids 1-42 in p53 comprise the transcriptional activation domain, and it is this region that binds MDM2. Residues 102-292 encode the sequence-specific DNA binding domain. p53 binds DNA as a tetramer, and the oligomerization domain is encoded by residues 327-355. In addition to affecting the DNA binding activity of p53, oligomerization has also been reported to affect the susceptibility of p53 to MDM2-mediated ubiquitination. For example, oligomerization-deficient mutants of p53 displayed low binding affinity for MDM2 and were relatively poor substrates for ubiquitination (25, 26) . However, efficient ubiquitination was restored when an oligomerization MDM2 can promote p53 degradation in trans 11 by guest on October 1, 2017 http://www.jbc.org/ Downloaded from deficient p53 mutant was fused to the dimerization domain of a heterologous protein (25) . These results indicated that oligomerization is required for wild-type p53 to efficiently bind and be targeted for ubiquitination by MDM2.
Several studies have reported that an intact MDM2 binding domain is necessary for p53 to be degraded by MDM2. In the current study, we examined whether the MDM2 binding domain of p53 could be provided in trans through oligomerization between two p53 molecules.
p53 proteins mutated in their MDM2 binding domains were unable to bind MDM2 directly, and were resistant to MDM2-mediated ubiquitination, nuclear export, and degradation when expressed with MDM2 alone in either Saos-2 cells (p53-null) or U2OS cells (wild-type p53).
However, these same p53 mutants formed a complex with MDM2 and were efficiently ubiquitinated, degraded, and exported from the nucleus when co-expressed with MDM2 and wild-type p53. Moreover, this effect required MDM2 binding by wild-type p53 as well as oligomerization between wild-type p53 and the MDM2-binding deficient p53 mutants. Taken together, these results support a model whereby MDM2-binding deficient forms of p53 can bind MDM2 indirectly through oligomerization with wild-type p53, and are subsequently targeted for ubiquitination, nuclear export and degradation. It should be noted that targeting of the MDM2-binding deficient p53 in U2OS cells required over-expression of the mutant with both wild-type p53 and MDM2, despite the fact that these cells express endogenous, wild-type p53 protein.
This could be because of the relatively low concentration of endogenous wild-type p53 compared to the over-expressed mutant, or because the pre-existing p53 in U2OS cells is already oligomerized and unavailable for oligomerization with the newly expressed mutant p53.
The mechanisms which regulate the nuclear export of p53 have not been fully clarified.
Original studies suggested that a nuclear export signal (NES) within MDM2 was necessary for MDM2 to promote p53 degradation (27) . Based on these findings, MDM2 was proposed to function as a molecular shuttle that would bind p53 and subsequently transport p53 from the MDM2 can promote p53 degradation in trans nucleus to the cytoplasm via the MDM2 NES. More recent studies have suggested that the ability of MDM2 to ubiquitinate p53, and not the MDM2 NES, is required for MDM2 to promote the nuclear export of p53. According to this model, the addition of ubiquitin moieties is thought to expose an NES within the p53 C-terminus, leading to the export of p53 from the nucleus to the cytoplasm (13, 14) . In the current study, MDM2 could promote the nuclear export of a p53 mutant which lacked the ability to bind MDM2 directly. Moreover, MDM2 remained nuclear under conditions in which either wild-type p53 or an MDM2-binding deficient mutant of p53 was exported to the cytoplasm (Figs. 4 and 5) . These results are most consistent with a model in which an activity of nuclear MDM2, and not MDM2 shuttling itself, is necessary to promote p53 nuclear export.
Our results also invite consideration of the mechanisms which regulate p53 in response to DNA damaging stress. Current models contend that the stabilization of p53 that occurs in response to DNA damage results from phosphorylation of p53 at one or more N-terminal sites.
These phosphorylations are thought to inhibit p53:MDM2 binding, and therefore stabilize the p53 protein (3, 20, 21, 28) . The premise of this model is that modifications to p53 which inhibit its interaction with MDM2 would result in stabilization of the p53 protein. However, p53 can exist as an oligomer of multiple p53 molecules, and it has not been determined how many p53 molecules within a p53 oligomer would need to lose MDM2-binding capacity in order for the whole oligomer to be stabilized. In the current study, p53 mutants deficient in MDM2-binding could oligomerize with wild-type p53 and bind MDM2 indirectly, and both the wild-type and mutant p53 proteins were then susceptible to MDM2-mediated degradation. This scenario may be considered similar to that in which an unmodified p53 molecule that can bind MDM2 oligomerizes with a phosphorylated p53 molecule that has lost MDM2-binding capacity in DNA damaged cells. In light of our results, we predict that the phosphorylated p53 could oligomerize with the unmodified p53 and bind MDM2 indirectly as a result of this oligomerization, and that both the unmodified and phosphorylated p53 molecules would then be susceptible to MDM2 can promote p53 degradation in trans Lysates from the cells transfected in Fig. 2 were examined for ubiquitination of the 
